US › Healthcare

Zevra Therapeutics Inc. (ZVRA)

US · Healthcare · Biotechnology

$10.52+4.62%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$36.2M
Revenue YoY
+77.5%
Net profit
$37.9M
Profit YoY
+1322.7%
EPS
$0.18
EPS estimate
$0.08
Net margin
104.6%

EPS came in at 0.18 against a street estimate of 0.08 — a beat of 125.0%.

Key statistics

Market cap
$594.4M
P/E
5.0
Forward P/E
8.8
P/B
2.73
Book value
$3.48
EPS (TTM)
$2.01
52-week high
$15.04
52-week low
$7.16
50-day MA
$12.19
200-day MA
$10.11
Beta
0.92

Analyst view

Analysts rate Zevra Therapeutics Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $25.00.

Shareholding

Insiders
1.28%
Institutions
74.22%

Largest institutional holders

FundStake
BlackRock Inc7.54%
Woodline Partners LP5.84%
FMR Inc5.43%
Nantahala Capital Management, LLC4.27%
Vanguard Capital Management, LLC4.18%
State Street Corp2.64%
Geode Capital Management, LLC2.32%
AIGH Capital Management, LLC2.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Zevra Therapeutics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.